Efficacy and safety of stem cells in the treatment of ischemic stroke: A meta-analysis

Yu Xiong,Xiumei Guo,Wen Gao,Chuhan Ke,Xinyue Huang,Zhigang Pan,Chunhui Chen,Hanlin Zheng,Weipeng Hu,Feng Zheng,Hao Yao

DOI: https://doi.org/10.1097/md.0000000000037414

IF: 1.6

2024-04-02

Medicine

Abstract:Ischemic stroke due to cerebral ischemia and hypoxia is a cerebrovascular disease with a high rate of disability. Ischemic stroke represents the main cause of disability and death worldwide. [ 1 ] The mortality rate of ischemic stroke within 30 days has been reported to range from 5% to 15%, and the disability rate may exceed 50%. [ 2 , 3 ] More than 40% of survivors experience ischemic stroke again, with even higher mortality and disability rates. [ 2 , 4 ] To date, recombinant tissue plasminogen activator standard intravenous thrombolytic therapy represents the only clinically approved drug therapy for acute cerebral infarction. However, this treatment has limitations, mostly linked to its application within a short window period of 4.5 hours following onset of symptoms. [ 5–7 ] Endovascular interventional therapy is also being increasingly used, but remains only applicable to patients with large vascular occlusions. [ 8 , 9 ] The disability rates for patients not eligible for either thrombolytic therapy or thrombectomy are even higher. Although rehabilitation treatment contributes to the recovery of neurological function, its curative effect remains limited. [ 10 , 11 ]

medicine, general & internal